Cencora, Inc. (NYSE:COR) Shares Sold by Stifel Financial Corp

Stifel Financial Corp cut its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 3.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 76,004 shares of the company's stock after selling 2,847 shares during the quarter. Stifel Financial Corp's holdings in Cencora were worth $17,121,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of COR. Pacer Advisors Inc. lifted its stake in Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock worth $464,874,000 after purchasing an additional 2,035,679 shares in the last quarter. Legal & General Group Plc lifted its stake in Cencora by 3.7% during the 2nd quarter. Legal & General Group Plc now owns 1,875,445 shares of the company's stock worth $422,538,000 after acquiring an additional 67,287 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Cencora by 1.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,552,213 shares of the company's stock valued at $349,372,000 after acquiring an additional 18,782 shares during the period. Swedbank AB grew its position in Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after acquiring an additional 31,104 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Cencora by 10.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,262,882 shares of the company's stock worth $284,544,000 after purchasing an additional 119,927 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on COR. Evercore ISI raised their price target on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Leerink Partners decreased their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research note on Monday, October 7th. Bank of America restated a "neutral" rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a report on Wednesday, August 21st. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $276.80.

Cencora Stock Performance

Shares of COR stock traded down $3.50 during mid-day trading on Tuesday, hitting $237.01. 1,485,621 shares of the stock were exchanged, compared to its average volume of 1,389,562. The stock's fifty day simple moving average is $237.43 and its two-hundred day simple moving average is $233.72. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a 12-month low of $195.83 and a 12-month high of $253.27. The stock has a market capitalization of $45.81 billion, a price-to-earnings ratio of 31.52, a P/E/G ratio of 1.62 and a beta of 0.45.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.93%. This is a boost from Cencora's previous quarterly dividend of $0.51. Cencora's payout ratio is currently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.